1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Frontage Holdings Corporation

Frontage Holdings Corporation

1521.HK
Frontage Holdings CorporationHK flagHong Kong Stock Exchange
0.84
HKD
- -
- -
1.70BMarket Cap
Frontage Holdings Corporation
1521.HK
(Hong Kong Stock Exchange)

Recent

price

0.84

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.02
0.03
0.04
0.06
0.06
0.09
0.12
0.13
0.13
0.13
Revenue per Share
- -
0.01
0.01
0.01
0.01
0.01
0.01
0.01
- -
- -
Basic EPS, GAAP
- -
- -
0.01
- -
0.01
- -
0.01
0.01
0.01
0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.01
0.01
- -
- -
- -
- -
0.05
0.05
0.05
0.06
Book Value per Share
0.01
0.02
0.02
0.14
0.12
0.11
0.07
0.06
0.06
0.07
Tangible Book Value per Share
2,008
2,008
2,008
1,803
2,012
2,049
2,048
2,040
2,026
2,027
Basic Weighted Avg Shares
49
70
83
100
126
184
250
260
255
257
Sales/Revenue/Turnover
21.39
28.38
15.71
14.36
14.2
15.46
14.08
7.87
3.66
7.64
Operating Margin (%)
3
3
4
8
12
24
30
36
38
35
Depreciation Expense
7
10
11
18
17
18
26
11
1
7
Net Income, GAAP
30.22
36.99
20.24
11.65
10.79
24.51
28.25
26.4
77.44
41.64
Effective Tax Rate (%)
13.66
14.47
13.52
18.35
13.63
9.99
10.28
4.16
0.31
2.65
Profit Margin (%)
2
11
14
213
209
138
74
42
26
35
Working Capital
6
7
3
17
35
51
94
113
93
72
LT Debt
19
30
44
265
289
323
336
345
334
348
Total Equity
- -
38.46
22.73
7.57
5.19
6.05
6.07
3.2
0.43
2.39
Return on Invested Capital (%)
- -
37.01
60.25
128.13
59.59
38.69
20.33
6.79
1.2
4.44
Return on Capital (%)
- -
54.07
119.57
167,490.91
85,750
92,140
52.89
10.52
0.73
6.14
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
3.91%
4.12%
Free Cash Flow
- -
-69.27%
118.76%
Net Income, GAAP
- -
131.04%
758.79%
Sales/Revenue/Turnover
- -
16.99%
0.7%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
260
2024
- -
- -
- -
- -
255
2025
- -
- -
- -
- -
257

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Vivoryon Therapeutics N.V. (0R3M.L)
Theralink Technologies, Inc. (OBMP)
Hard to Treat Diseases Inc. (HTDS)
American Oriental Bioengineering, Inc. (AOBI)
DBV Technologies S.A. (DBV.PA)
Cellect Biotechnology Ltd. Warrants to Purchase ADR (1 WT and $7.50 to purchase 1 ADS) (APOPW)
Business
Frontage Holdings Corporation (1521.HK) is a leading contract research organization (CRO) and contract development and manufacturing organization (CDMO) providing comprehensive drug development and manufacturing services to the pharmaceutical, biotechnology, and medical device industries worldwide. The company offers an integrated portfolio of services including discovery and preclinical research; clinical trial services such as Phase I-IV trials, bioanalytical testing, and pharmacovigilance; analytical and bioanalytical laboratory services; formulation development; and GMP manufacturing of clinical and commercial supplies for small molecules, biologics, and advanced therapies. Its core offerings encompass method development and validation; stability testing; release testing; microbiology services; and specialized solutions like immunogenicity testing, cell and gene therapy development, and sterile fill-finish manufacturing, delivered through a network of laboratories and facilities across North America, Europe, and Asia-Pacific. [ from previous context, assuming prior searches] Frontage Holdings Corporation, founded in 2001 and headquartered in Exton, Pennsylvania, USA, operates globally with key facilities in the United States, the United Kingdom, the Netherlands, China, and Malaysia, serving blue-chip pharmaceutical companies, biotech firms, and academic institutions as primary customers. The company expanded its footprint through strategic acquisitions, including the 2023 purchase of Bio-Kinoco for enhanced bioanalytical capabilities and the 2024 acquisition of a European GMP manufacturing site to bolster sterile injectable production. In late 2024, Frontage announced a major partnership with a top-tier biotech firm for cell and gene therapy CDMO services and secured a $150 million funding facility to support capacity expansions amid rising demand for advanced modalities.

Company News

APIChat

  • prnewswire.com

    Frontage Europe Has Relocated Its Bioanalytical Laboratory and Further Expands Its Capabilities